EyePoint stock: buy or sell?
November 15th, 2019
Should I buy EyePoint stock?Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. That's why is so important to choose your own trading plan that fits your character as inversor. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
Currently, EyePoint Pharmaceuticals stock doesn't match any of these trading strategies, so our recommendation is not to buy.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is EyePoint Pharmaceuticals stock a buy?
Financial institutions and banks publish stock ratings everyday.At Stocks2.com, we detected 3 ratings published for EYPT stock in the last month.
|Date||Analyst / Broker||Previous rating||Current rating|
EyePoint stock analysis
EyePoint ended yesterday at $1.38 and dropped a terrible -2.82%.
Shares of EyePoint Pharmaceuticals dropped a terrible -2.82% and closed at $1.38. Since price and SMA200d lines crossed down on Nov/7, EYPT fell $-0.93 per share (-40.26%). For the last 39 days when SMA50d and SMA100d crossed up, EYPT price slipped $-0.79 per share (-36.41%).
EyePoint Pharmaceuticals shares plunged -4.83% this week, ending at $1.38. Late October EYPT rocketed an outstanding 7.17% in just one week.
EyePoint Pharmaceuticals stock fell under the support line what triggered further losses. Possible next supports for EYPT stock are 1.26. Since last week, when EYPT stock price broke down the 40-weeks moving avarage line, it slid $-0.99 per share (-41.77%). Stocks below the 200d moving average line are usually not recommended for average traders.
EyePoint stock price history
EyePoint IPO was on January 27th, 2005 at $42.00 per share1. Since then, EYPT stock lost a -96.70%, with a yearly average of -6.90%.
1: Adjusted price after possible price splits or reverse-splits.
EyePoint stock historical price chart
EYPT stock reached 52-week highs on February at $2.82, and all-time highs 2005-01-27 with a price of 48.56.
EyePoint stock price target is $4.20How much a stock will be priced tomorrow or next week is quite unpredictable However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. For the last month we found 3 price predictions for EYPT stock:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-9-24||B. Riley||Lowers Target||$5.75||$4.00||-30.4%|
Financials and fundamental analysis
Earnings date and Earnings per ShareOn March, EyePoint missed the forecasts of the analysts and posted a fatal EPS of $-0.12 per share when experts were expecting $-0.14.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsCompared to 2017, last anual revenues report draw a scary loss of -60.72% to $2.96 million USD. When comparing 2018 vs 2017, likewise, profit margin (that is, the net income divided by revenues) plunged a -1,550.52% to -1,795.71%. To have an up to date picture of the financial situation of EyePoint Pharmaceuticals, we have calculated the trailing twelve month (TTM) sales and income figures. TTM values are the sum of the last 4 quarters and aproximate to an annual fiscal report ending in 2018-Q4 that can be compared to 2018 fiscal year results. Annual EyePoint Pharmaceuticals TTM sales up to December 2018 were $4.57 and income was $-86.13 M USD. When comparing this TTM figures with the last reported annuality, we can review EyePoint business evolution since June 2018: Annual revenues up to December, compared to lastest yearly report, climbed an amazing 54.37%. In contrast, profit margin (net income/sales) plummed at -1,795.71%.
|2013||$2.14 M||-||$-11.90 M-556.1%||-|
|2014||$3.47 M||62.15%||$-13.36 M-385.0%||12.27%|
|2015||$27 M||665.56%||$6.35 M23.9%||-147.51%|
|2016||$1.62 M||-93.90%||$-21.55 M-1330.1%||-439.48%|
|2017||$7.54 M||365.37%||$-18.49 M-245.2%||-14.21%|
|2018||$2.96 M||-60.72%||$-53.17 M-1795.7%||187.64%|
|TTM||$4.57 M||54.37%||$-86.13 M-1884.2%||61.98%|
Quarterly financial resultsEyePoint Pharmaceuticals posted $2.44 M in revenues for 2018-Q4, a 402.47% improvement compared to previous quarter. Reported quarter earnings marked $-11.59 M with a profit margin of -474.77%. Profit margin climbed a 6,341.27% compared to previous quarter when profit margin was -6,816.05%. When comparing turnover to same quarter last year, EyePoint sales marked an astounding increase and skyrocketed a 161.74%.
|2017-Q1||$0.59 M||-||$-5.14 M-871.2%||-|
|2017-Q2||$0.70 M||18.81%||$-6.12 M-873.0%||19.07%|
|2017-Q3||$0.39 M||-45.08%||$-5.98 M-1554.0%||-2.24%|
|2017-Q4||$0.93 M||142.34%||$-5.78 M-619.7%||-3.36%|
|2018-Q1||$0.93 M||-0.54%||$-6.98 M-751.9%||20.68%|
|2018-Q2||$0.72 M||-22.95%||$-34.43 M-4815.1%||393.38%|
|2018-Q3||$0.49 M||-32.03%||$-33.13 M-6816.0%||-3.78%|
|2018-Q4||$2.44 M||402.47%||$-11.59 M-474.8%||-65.00%|
EyePoint ownershipWhen you are planning to buy shares of a company, it's always worth to review its ownership structure.
EyePoint shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 5.50% of all shares.
In case of EyePoint stock, 55.84% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for EYPT stock account 0.00%, no big difference from last month.
For a better understanding, the next table shows ownership data compared to other related companies:
|Market cap||$149.2 M|
|Total shares||108.1 M|
|Float shares||59.5 M|
|- Institutional holdings (%)||55.8%|
|- Insider holdings (%)||5.5%|
|Shares in short selling||0.0%|
|Friday, November 15th, 2019|
|Day range||$1.35 - $1.45|
|Average true range||$0.21|
|50d mov avg||$1.98|
|100d mov avg||$1.72|
|200d mov avg||$1.85|
EyePoint performanceTo measure stock performance is always good to benchmark with competitors or related stocks. We compared EyePoint against in the following table: